Skip to main content
Clinical Trials/NCT06547684
NCT06547684
Recruiting
Not Applicable

Effects of Focused Extracorporeal Shock Wave Therapy on Spastic Equinus Foot in Stroke Patients: a Randomized Controlled Trial

Teresa Mateu Campos1 site in 1 country60 target enrollmentAugust 28, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Teresa Mateu Campos
Enrollment
60
Locations
1
Primary Endpoint
Modified Ashworth Scale (MAS)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this study is to evaluate long term effects of focused extracorporeal shock wave therapy (fESWT) on triceps surae spasticity in stroke patients according to the number of sessions applied.

Hypothesis: 3 sessions of fESWT on equinus foot in stroke patients improve spasticity and functionality for longer term than 1 session of fESWT.

Detailed Description

Spasticity is a common complication as a consequence of suffering a stroke and one of the most important causes of disability in this pathology. Global data estimate that 12 million people world-wide suffer from spasticity of the upper or lower limb. Equinus foot is the most common pattern of the lower extremities. Previous studies have reported that extracorporeal shock wave therapy (ESWT) is a safe and noninvasive alternative treatment for spasticity. Although the authors have shown a beneficial clinical effect of the ESWT, outcomes and duration of effect varied across studies. This is a prospective randomized controlled trial. 60 stroke patients with spastic equinus foot post stroke will enroll in this study. The participants will be randomly divided into two groups. The first group (control group) will receive 1 session of fESWT, while the second group (experimental group) will receive 3 sessions of fESWT, once a week, for 3 consecutive weeks. Therapy will be administered directly to the muscle bellies of the gastrocnemius medial and lateral and soleus. The muscle belly will be located by ultrasonography. The primary outcome is modified Ashworth scale. Secondary outcomes are passive range of ankle motion, mobility and balance test, spasm frequency scale and quality of life scales. Participants will be evaluated by the same researcher before the first shock wave therapy and after the last session of fESWT will be done periodic revisions on weeks 1, 4, 8, 12, 20, 24, 36 and 48. Adverse events will be monitored during the study.

Registry
clinicaltrials.gov
Start Date
August 28, 2020
End Date
August 7, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Teresa Mateu Campos
Responsible Party
Sponsor Investigator
Principal Investigator

Teresa Mateu Campos

Principal Investigator

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Eligibility Criteria

Inclusion Criteria

  • Age greater than 18 years old
  • Time from stroke (ischemic o hemorrhagic) onset of at least 6 months
  • Spastic equinus foot: triceps surae tone grade at least 1+ on the MAS score
  • Ability to walk alone with or without aids

Exclusion Criteria

  • Fixed ankle joint contracture
  • Severe medical problems
  • Treatment of the affected leg with botulinum toxin in the las 6 months
  • Cognitive impairment

Outcomes

Primary Outcomes

Modified Ashworth Scale (MAS)

Time Frame: Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.

A manual measurement of the resistance os muscles during passive stretching. Score from 0 to 4, higher scores mean a worse outcome

Secondary Outcomes

  • Visual Analogue Scale (VAS) Pain Score(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)
  • Test Up and Go (TUG)(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)
  • Spasm Frequency Scale(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)
  • Fall Skip Device(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)
  • Stroke Quality of Life Scale (ECVI-38)(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)
  • Passive Ankle range of motion (PROM)(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)
  • 10 Meters Walk Test(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)
  • Test 6 Minutes Walking(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)
  • Self Report Spasticity Scale (SRSS)(Before the first shock wave therapy and 1,4,8,12,20,24,36 and 48 weeks after the last session of ESWT.)

Study Sites (1)

Loading locations...

Similar Trials